title: Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
abstract: Down-regulation of E-cadherin, an intercellular adhesion molecule, and up-regulation of autocrine motility factor receptor (gp78) expressions have been shown to play a role in tumor cell invasion and metastasis. Monoclonal antibodies against E-cadherin and gp78 were used to stain serial snap-frozen sections of 12 normal bladder and 83 bladder carcinoma specimens (27 noninvasive, 53 invasive, and 3 metastases). In normal urothelium, E-cadherin is expressed while gp78 is not. Positive expression of E-cadherin and negative expression of gp78 were found to be associated with a low risk of clinical progression in the superficial bladder carcinoma patient group. While reduction in E-cadherin concomitantly with an increase in gp78 expression was associated with poor prognosis, 71% of the patients (n = 30) underwent rapid cancer progression, and 32% of the patients died of cancer-related disease at a median of 2 years after initial diagnosis. Thus, it is suggested that reduction of E-cadherin expression associated with an increase in the level of gp78 in bladder cancers may define a high risk group of patients. The dual use of these two antigens may improve early diagnosis of high risk bladder cancer patients and influence treatment decisions.
authors.affiliation: Department of Urology, University of Essen, Medical School, Federal Republic of Germany.
authors.forename: T
authors.initials: T
authors.lastname: Otto
authors.forename: W
authors.initials: W
authors.lastname: Birchmeier
authors.forename: U
authors.initials: U
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Hinke
authors.forename: J
authors.initials: J
authors.lastname: Schipper
authors.forename: H
authors.initials: H
authors.lastname: Rübben
authors.forename: A
authors.initials: A
authors.lastname: Raz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis; D015820:Cadherins / Q000032:analysis* / Q000502:physiology*; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D060285:Receptors, Autocrine Motility Factor; D018121:Receptors, Cytokine / Q000032:analysis* / Q000502:physiology*; D012189:Retrospective Studies; D044767:Ubiquitin-Protein Ligases; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D015820:Cadherins; D018121:Receptors, Cytokine; C555000:AMFR protein, human; D060285:Receptors, Autocrine Motility Factor; D044767:Ubiquitin-Protein Ligases